Pharmaceutical Benefits Advisory Committee submission
Pharmaceutical Benefits Advisory Committee (PBAC)
Submission by ADHD Australia in June 2019
ADHD Australia recently made an online submission to the next meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) which is to be held in July.
ADHD Australia undertook this advocacy step on behalf of all those living with ADHD in an effort to bring to the attention of PBAC the inequitable way in which some medications are being made available to one part of the ADHD diagnosed community and not another. There are some medications being provided at the discounted rate on the Public Benefits Scheme (PBS) to individuals with ADHD just because they had their diagnosis as a child or adolescent. ADHD Australia believes that there should be no age discrimination on the PBS availability of medications stemming from the age of the individual at diagnosis. Below is the excerpt from our submission to PBAC.
Excerpt from our online submission
“ADHD Australia believes that equitable access to comprehensive, multi-disciplinary care is key to ensuring that people living with Attention Deficit Hyperactivity Disorder (ADHD) are able to achieve their full potential. Unfortunately, it is only in recent times that the validity of the concept of ADHD as a legitimate and debilitating neurodevelopmental disorder has achieved mainstream medical recognition.
The fact that the core deficits of ADHD pose challenges for the majority of sufferers throughout their lives is still grossly underappreciated. The net result of these factors is that many adults with ADHD were not afforded the benefit of diagnosis in their early life (childhood and adolescence). Under current PBS reimbursement criteria these patients are unable to access long-acting medications to treat their core symptoms.
There is evidence to suggest that girls with ADHD are less likely to be accurately diagnosed and it is well known that people from lower socioeconomic groups have poorer access to the quality of care that would enable accurate diagnosis in childhood.
Taken together these factors demonstrate that the current “age of diagnosis” criterion for allowing access to long-acting medications is highly discriminatory and needs to be removed.”
To read more about PBAC please visit their website at: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-consumer-comments.